Pluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced the appointment of Dr. Hillard Lazarus of Case Western Reserve University as the Principal Investigator of the Company's Phase I trial of its PLacental eXpanded (PLX)-R18 cells to treat incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT).
View full press release